Research interests

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Lorem ipsum dolor sit amen

No items found.

JPND/Horizon 2020-funded project including patients with pre-demented Alzheimer’s disease to find biomarkers for small vessel damage in the brain.

Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.

Highlighted work

2024

ACHE

AcuteHeadache Evaluation Study. (PIEspen Saxhaug Kristoffersen). Funding by Ahus.

2023

MultiHead

Multidisciplinary HeadacheTreatment. (PI Kjersti Grøtta Vetvik). Effect of headache treatment in amultidisciplinary team on headache burden and work participation. A cooperationwith the Norwegian Labour and welfare administration (NAV).

2024

Resolution

(PI Christofer Lundqvist) –Treatmentwith Eptinezumab in medication overuse headache. Sponsor Lundbeck AS.

2024

CandMig

PIChristofer Lundqvist). Candesartan for migraine. CandMig III:Kandesartan som forebyggende medisin ved hyppig migrene - Cristin. Fundedby Klinbeforsk.

2023

BioCer

(PIEspen Saxhaug Kristoffersen). Home-basedbiofeedback as a migraine treatment. Funded by the Norwegian Headache researchcenter (NorHead) and Nordic Brain tech.

www.biocer.no

Publications

Prevalence of headache disorders in Norway: results from the population based PopHEAD study

PubMed↗

Argren MB, Engstrand H, Husøy AK, ..., Winsvold BS

November 26, 2025

Headache in individuals undergoing hormone therapy for gender transition: A cross-sectional, observational study

PubMed↗

Zavala LJ, Gil Ramirez A, Vetvik KG, ..., Hougaard A

October 16, 2025

Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial

PubMed↗

Øie LR, Wergeland T, Salvesen Ø, ..., Tronvik E

September 17, 2025

Ongoing projects and clinical trials

BioTenCer. (PI Kjersti Grøtta Vetvik). Biofeedback as Preventive Treatment in Tension Type Headache. Funded by the Norwegian Headache research center (NorHead) and Nordic Brain tech. www.biocer.no
MultiHead - Multidisciplinary Headache Treatment. (PI Kjersti Grøtta Vetvik). Effect of headache treatment in a multidisciplinary team on headache burden and work participation. A cooperation with the Norwegian Labour and welfare administration (NAV).
EpisodicStatinMig (PI Kjersti Grøtta Vetvik). A multicentre, triple blind, placebo controlled, parallel group study of atorvastatin in episodic migraine. Funded by Klinbeforsk.
Chronic StatinMig (PI Kjersti Grøtta Vetvik). A multicentre, triple blind, placebo controlled, parallel group study of atorvastatin in chronic migraine. Funded by Klinbeforsk.
ACHE - Acute Headache Evaluation Study. (PI Espen Saxhaug Kristoffersen). Funding by Ahus.
Episodic CandClus2. (PI Kjersti Grøtta Vetvik). A randomized, placebo-controlled, triple blind study of candesartan in adults with episodic cluster headache. Funded by Klinbeforsk.
Chronic CandClus2. (PI Kjersti Grøtta Vetvik). A randomized, placebo-controlled, triple blind study of candesartan in adults with chronic cluster headache. Funded by Klinbeforsk.

Infrastructure

Norwegian Centre for Headache Research – NorHead

The headache group is partner and leads the Operational Unit (OU) for clinical implementation in NorHead, which unites the leading experts on headache disorders in Norway, across disciplines. Through NorHead we have collaborators at all university Hospitals and in all health regions in Norway as well as international collaborators. NorHead is funded by the Research Council of Norway with 128 mill Norwegian kroner as a Centre for Clinical Treatment Research. In addition, participating universities and hospitals in Norway contribute with half of the funding.